Study #2021-1173
A Phase 2 Study of Neoadjuvant Lenvatinib in Locally Advanced Invasive Thyroid Cancer
MD Anderson Study Status
Not Accepting
Treatment Agent
LENVATINIB
Description
This research is being done to evaluate the safety and efficacy of neoadjuvant lenvatinib on surgical outcomes of patients with invasive extrathyroidal differentiated thyroid cancer (DTC). This research study involves a study drug called lenvatinib
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Differentiated Thyroid Cancer, Advanced Cancer
Study phase:
Phase II
Physician name:
Naifa Busaidy
Department:
Endocrine Neoplasia and HD
For general questions about clinical trials:
1-888-448-0874
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.